News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Market source Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
NeuroOne Medical Technologies (NMTC) reported a deeper net loss of $2.01 million for Q3 2026 and $5.83 million for the nine months ended June 30, 2026, significantly larger than the previous year. The company's cash and cash equivalents dwindled to $2.05 million, leading management …
This article announces that Neuroone Medical Technologies Corp filed a Form 8K on August 13. It includes the company's stock symbol (NMTC) and its current performance. The content primarily serves as a placeholder for the filing and does not provide further details about the …
NeuroOne (NMTC) reported a 16% increase in Q3 FY2026 product revenue to $1.97 million, with product gross margin expanding to 59.9%. Despite a net loss of $2.01 million, the company secured $2.7 million in new product orders and achieved ISO 13485:2016 certification. Significant progress …
NeuroOne Medical Technologies Corporation reported strong fiscal Q3 2026 financial results, with product revenue increasing 16% year-over-year to $2.0 million and gross margins expanding to 59.9%. The company also announced $2.7 million in new product orders, received ISO 13485 Certification for international expansion, and …
NeuroOne Medical Technologies Corporation has announced it received ISO 13485-2016 certification, an international standard for Quality Management Systems in the Medical Device Industry. This certification allows NeuroOne to pursue international marketing opportunities for its Evo® Cortical and Evo® sEEG Electrodes, and the OneRF® Brain …
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced it will release its fiscal third quarter financial results for the period ended June 30, 2026, before market open on August 13, 2026. The company will host an investor conference call and webcast on the same day …
This article provides an overview of NeuroOne Medical Technologies Corp (NMTC), including its current stock price and market capitalization. It indicates that relevant data for the company's revenue breakdown by business segments and regions has not yet been disclosed. The page is primarily a …
NeuroOne Medical Technologies has released a white paper detailing its StereoCED(TM) platform, designed for scalable CNS drug delivery. The platform aims to streamline robotic-assisted intracranial drug delivery, addressing challenges in existing methods for cell and gene therapies. NeuroOne anticipates the device will be available …
This article provides a risk assessment for NeuroOne Medical Technologies Corp (NMTC), ranking it 157 out of 199 in the Healthcare Equipment & Supplies industry with a score of 2.21. It highlights NMTC's beta value of 0.53, indicating lower volatility compared to the S&P …
NeuroOne Medical Technologies announced positive physician experiences with its OneRF® Ablation System at the Mayo Clinic in Jacksonville, Florida, for treating drug-resistant focal epilepsy. A cohort of 25 patients showed meaningful reductions in seizure frequency and improved quality of life with rare short-term effects …
NeuroOne Medical Technologies Corp (NMTC) has distributed no dividends over the past five years. The company has a recorded stock split event, specifically a 6-to-1 merger, which occurred on April 14, 2026. The stock is currently trading at 1.706 USD, down 3.04%, with a …
This article analyzes the financial health of NeuroOne Medical Technologies Corp (NMTC), giving it a current financial score of 7.45, ranking it 83rd in the Healthcare Equipment & Supplies industry. NMTC shows robust financial status with low operating efficiency, reporting a 72.46% year-over-year revenue …
This article provides a detailed cash flow statement for NeuroOne Medical Technologies Corp (NMTC), presenting annual and quarterly data across operating, investing, and financing activities. It includes breakdowns of various cash flow components and frequently asked questions explaining key terms like operating cash flow, …
This article provides a detailed overview of NeuroOne Medical Technologies Corp (NMTC), including its current stock price, key financial figures, stock performance over various periods, and analyst ratings. It highlights the company's focus on developing minimally invasive solutions for neurological disorders and lists its …
NeuroOne Medical Technologies Corp's institutional shareholding score is 3.00, placing it 131st in the Healthcare Equipment & Supplies industry. Institutional ownership stands at 28.07%, a 16.20% decrease quarter-over-quarter. James Simons is the largest institutional shareholder, holding 1.29% of outstanding shares.
NeuroOne Medical Technologies Corp (NMTC) shows relatively healthy fundamentals and significant growth potential, although its valuation is considered fairly valued within the Healthcare Equipment & Supplies industry. Despite a recent weak stock market performance, the company's revenue has grown consistently, averaging 250.82% year-on-year over …
Search by ticker symbol or company name and select a result to open its chart.